Dianthus Therapeutics DNTH Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's total liabilities & equity?
- Dianthus Therapeutics (DNTH) reported total liabilities & equity of $1.25B in Q1 2026.
- How has Dianthus Therapeutics's total liabilities & equity changed year-over-year?
- Dianthus Therapeutics's total liabilities & equity increased by 257.7% year-over-year, from $348.58M to $1.25B.
- What is the long-term trend for Dianthus Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's total liabilities & equity has grown at a 26.9% compound annual growth rate (CAGR), from $161.62M to $530.92M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.